铂-话题@MedSci

#铂#

382篇内容 | 6027人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1737470, encodeId=f5fd1e37470d1, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=ESMO 2014：吉西他滨联合顺铂(GP)或紫杉醇(GT)一线治疗复发或转移性三阴性乳腺癌获良好疗效(CBCSG006试验), objectType=article, longId=40873, objectId=e833408e36f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e833408e36f, replyNumber=0, likeNumber=79, createdTime=2015-08-10, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e833408e36f, moduleTitle=ESMO 2014：吉西他滨联合顺铂(GP)或紫杉醇(GT)一线治疗复发或转移性三阴性乳腺癌获良好疗效(CBCSG006试验), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e833408e36f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737459, encodeId=9df21e37459ce, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=ASCO 2014：尼妥珠单抗+紫杉醇、顺铂一线治疗食管鳞癌更优, objectType=article, longId=35650, objectId=d127356506e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d127356506e, replyNumber=0, likeNumber=64, createdTime=2014-11-11, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d127356506e, moduleTitle=ASCO 2014：尼妥珠单抗+紫杉醇、顺铂一线治疗食管鳞癌更优, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d127356506e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737469, encodeId=0ef71e37469bd, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=阿瓦斯汀铂类耐药复发性卵巢癌新适应症获欧盟批准, objectType=article, longId=38954, objectId=3ffd3895492, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ffd3895492, replyNumber=0, likeNumber=90, createdTime=2015-05-04, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ffd3895492, moduleTitle=阿瓦斯汀铂类耐药复发性卵巢癌新适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ffd3895492)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737458, encodeId=e7971e3745866, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=ASCO 2014：5-FU和顺铂治疗晚期鼻咽癌的药代动力学和遗传药理学分析, objectType=article, longId=35644, objectId=12f33564411, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12f33564411, replyNumber=0, likeNumber=70, createdTime=2014-12-08, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12f33564411, moduleTitle=ASCO 2014：5-FU和顺铂治疗晚期鼻咽癌的药代动力学和遗传药理学分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12f33564411)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737466, encodeId=4a741e374660c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Ann Pharmacother：甘露醇可能减轻顺铂的肾毒性风险, objectType=article, longId=38292, objectId=376d38292e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=376d38292e6, replyNumber=0, likeNumber=90, createdTime=2014-10-11, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=376d38292e6, moduleTitle=Ann Pharmacother：甘露醇可能减轻顺铂的肾毒性风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=376d38292e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737457, encodeId=8d3e1e37457ee, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Chem Comm：阿司匹林帮助顺铂击败耐药性, objectType=article, longId=31931, objectId=93463193105, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93463193105, replyNumber=0, likeNumber=61, createdTime=2014-12-06, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93463193105, moduleTitle=Chem Comm：阿司匹林帮助顺铂击败耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93463193105)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737474, encodeId=ac871e3747431, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=ASCO GI 2015：S-1/顺铂可作为晚期胃癌新辅助化疗方案（COMPASS研究）？, objectType=article, longId=45955, objectId=807c4595549, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=807c4595549, replyNumber=0, likeNumber=82, createdTime=2015-08-18, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=807c4595549, moduleTitle=ASCO GI 2015：S-1/顺铂可作为晚期胃癌新辅助化疗方案（COMPASS研究）？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=807c4595549)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737463, encodeId=7a9f1e37463b7, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=S-1/奥沙利铂 (SOX)联合贝伐珠单抗与5-FU/l-LV/奥沙利铂(mFOLFOX6)联合贝伐珠单抗治疗转移性结直肠癌(mCRC)(SOFT研究), objectType=article, longId=37048, objectId=c4a63e048dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4a63e048dd, replyNumber=0, likeNumber=82, createdTime=2015-03-14, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4a63e048dd, moduleTitle=S-1/奥沙利铂 (SOX)联合贝伐珠单抗与5-FU/l-LV/奥沙利铂(mFOLFOX6)联合贝伐珠单抗治疗转移性结直肠癌(mCRC)(SOFT研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4a63e048dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737461, encodeId=606c1e3746196, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=吉西他滨联合S-1对比吉西他滨联合顺铂治疗晚期胆管癌的随机III期研究：一项日本临床肿瘤研究组的新研究（JCOG1113）, objectType=article, longId=37046, objectId=47363e0462c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47363e0462c, replyNumber=0, likeNumber=59, createdTime=2014-09-23, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47363e0462c, moduleTitle=吉西他滨联合S-1对比吉西他滨联合顺铂治疗晚期胆管癌的随机III期研究：一项日本临床肿瘤研究组的新研究（JCOG1113）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47363e0462c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737456, encodeId=6b3f1e37456de, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=JTD：NSCLC患者术后对多西他赛/卡铂辅助治疗耐受良好, objectType=article, longId=27339, objectId=dd7d2e339fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd7d2e339fc, replyNumber=0, likeNumber=69, createdTime=2014-07-18, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd7d2e339fc, moduleTitle=JTD：NSCLC患者术后对多西他赛/卡铂辅助治疗耐受良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd7d2e339fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737460, encodeId=e6091e37460f8, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=恒瑞医药抗癌药奥沙利铂通过FDA认证, objectType=article, longId=37012, objectId=f9493e01253, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9493e01253, replyNumber=0, likeNumber=101, createdTime=2015-06-01, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9493e01253, moduleTitle=恒瑞医药抗癌药奥沙利铂通过FDA认证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9493e01253)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737467, encodeId=be151e374674e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=JCO：培美曲塞联合顺铂治疗晚期宫颈癌安全有效, objectType=article, longId=38730, objectId=486438e3037, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=486438e3037, replyNumber=0, likeNumber=61, createdTime=2014-12-12, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=486438e3037, moduleTitle=JCO：培美曲塞联合顺铂治疗晚期宫颈癌安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=486438e3037)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737462, encodeId=496f1e374622a, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Gynecol Oncol：吉非替尼联合S-1与卡铂一线治疗发生表皮生长因子受体突变的晚期非小细胞肺癌患者的II期临床试验, objectType=article, longId=37047, objectId=6eb73e0471c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6eb73e0471c, replyNumber=0, likeNumber=27, createdTime=2014-08-21, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6eb73e0471c, moduleTitle=Gynecol Oncol：吉非替尼联合S-1与卡铂一线治疗发生表皮生长因子受体突变的晚期非小细胞肺癌患者的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6eb73e0471c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737451, encodeId=65db1e37451b4, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Gynecol Oncol：Farletuzumab用于对铂敏感的复发性卵巢癌, objectType=article, longId=20587, objectId=f70a2058ed6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f70a2058ed6, replyNumber=0, likeNumber=65, createdTime=2013-11-30, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f70a2058ed6, moduleTitle=Gynecol Oncol：Farletuzumab用于对铂敏感的复发性卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f70a2058ed6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737454, encodeId=a5e61e3745455, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=BOA2013：奥拉帕尼维持治疗可使BRCA突变性和铂敏感的复发性浆液性卵巢癌患者获益, objectType=article, longId=21190, objectId=fcdc211904f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcdc211904f, replyNumber=0, likeNumber=57, createdTime=2014-03-01, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcdc211904f, moduleTitle=BOA2013：奥拉帕尼维持治疗可使BRCA突变性和铂敏感的复发性浆液性卵巢癌患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcdc211904f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737453, encodeId=46071e374534b, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=BOA 2013：每周卡铂+紫杉醇治疗方案不能改善晚期卵巢癌生存, objectType=article, longId=21189, objectId=e6772118915, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6772118915, replyNumber=0, likeNumber=63, createdTime=2013-12-30, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6772118915, moduleTitle=BOA 2013：每周卡铂+紫杉醇治疗方案不能改善晚期卵巢癌生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6772118915)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737447, encodeId=7c7e1e374477d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Lancet Oncol：在卡培他滨-顺铂基础上联用西妥昔单抗不能改善晚期胃癌患者临床预后, objectType=article, longId=18831, objectId=158c1883170, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=158c1883170, replyNumber=0, likeNumber=58, createdTime=2013-09-17, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=158c1883170, moduleTitle=Lancet Oncol：在卡培他滨-顺铂基础上联用西妥昔单抗不能改善晚期胃癌患者临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=158c1883170)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737455, encodeId=c2641e37455d9, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=WCLC 2013：新药“加盟”能否超越含铂双药？No, objectType=article, longId=26420, objectId=7c232642032, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c232642032, replyNumber=0, likeNumber=87, createdTime=2014-01-14, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c232642032, moduleTitle=WCLC 2013：新药“加盟”能否超越含铂双药？No, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c232642032)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737450, encodeId=5bd71e37450f7, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=JCO:非小细胞肺癌（NSCLC）患者可加用卡铂, objectType=article, longId=19603, objectId=75f6196034c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75f6196034c, replyNumber=0, likeNumber=62, createdTime=2014-03-13, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75f6196034c, moduleTitle=JCO:非小细胞肺癌（NSCLC）患者可加用卡铂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75f6196034c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737446, encodeId=f6c91e3744614, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Lung Cancer：rs2269577可加重晚期NSCLC患者接受铂类治疗时的胃肠毒性, objectType=article, longId=17874, objectId=f2621e8740a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2621e8740a, replyNumber=0, likeNumber=60, createdTime=2013-11-07, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2621e8740a, moduleTitle=Lung Cancer：rs2269577可加重晚期NSCLC患者接受铂类治疗时的胃肠毒性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2621e8740a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

铂

2020-05-29

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

ESMO 2014：吉西他滨联合顺铂(GP)或紫杉醇(GT)一线治疗复发或转移性三阴性乳腺癌获良好疗效(CBCSG006试验)

2015-08-10

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

ASCO 2014：尼妥珠单抗+紫杉醇、顺铂一线治疗食管鳞癌更优

2014-11-11

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

阿瓦斯汀铂类耐药复发性卵巢癌新适应症获欧盟批准

2015-05-04

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

ASCO 2014：5-FU和顺铂治疗晚期鼻咽癌的药代动力学和遗传药理学分析

2014-12-08

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Ann Pharmacother：甘露醇可能减轻顺铂的肾毒性风险

2014-10-11

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Chem Comm：阿司匹林帮助顺铂击败耐药性

2014-12-06

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

ASCO GI 2015：S-1/顺铂可作为晚期胃癌新辅助化疗方案（COMPASS研究）？

2015-08-18

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

S-1/奥沙利铂 (SOX)联合贝伐珠单抗与5-FU/l-LV/奥沙利铂(mFOLFOX6)联合贝伐珠单抗治疗转移性结直肠癌(mCRC)(SOFT研究)

2015-03-14

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

吉西他滨联合S-1对比吉西他滨联合顺铂治疗晚期胆管癌的随机III期研究：一项日本临床肿瘤研究组的新研究（JCOG1113）

2014-09-23

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

JTD：NSCLC患者术后对多西他赛/卡铂辅助治疗耐受良好

2014-07-18

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

恒瑞医药抗癌药奥沙利铂通过FDA认证

2015-06-01

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

JCO：培美曲塞联合顺铂治疗晚期宫颈癌安全有效

2014-12-12

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Gynecol Oncol：吉非替尼联合S-1与卡铂一线治疗发生表皮生长因子受体突变的晚期非小细胞肺癌患者的II期临床试验

2014-08-21

医者仁心 (审核中...)

前往app查看评论内容

#铂#

Gynecol Oncol：Farletuzumab用于对铂敏感的复发性卵巢癌

2013-11-30

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

BOA2013：奥拉帕尼维持治疗可使BRCA突变性和铂敏感的复发性浆液性卵巢癌患者获益

2014-03-01

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

BOA 2013：每周卡铂+紫杉醇治疗方案不能改善晚期卵巢癌生存

2013-12-30

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Lancet Oncol：在卡培他滨-顺铂基础上联用西妥昔单抗不能改善晚期胃癌患者临床预后

2013-09-17

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

WCLC 2013：新药“加盟”能否超越含铂双药？No

2014-01-14

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

JCO:非小细胞肺癌（NSCLC）患者可加用卡铂

2014-03-13

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Lung Cancer：rs2269577可加重晚期NSCLC患者接受铂类治疗时的胃肠毒性

2013-11-07

科室
- - 订阅+
  - 更多科室
工具
服务